Assessment of Patient Use of a New Device: RebiSmart

NCT01195870 | Completed

• 1 other identifier: EMR701068-514
• Study Type: observational
• Target: 63
• Locations: 0 countries
• Sites: N/A

Brief Summary

Multiple sclerosis (MS) is a chronic disease which causes inflammation and destruction of the nerves in within the brain and the spinal cord. This disease is one of the most common causes of disability in young adults. A ''relapse'' is a phenomenon that occurs when there is an acute attack of disability as a result of an acute attack on the nervous system. There is usually some degree of recovery after a relapse. Rebif is licensed in the United Kingdom for the treatment of relapsing MS and is given 3 times a week by injections under the skin. The RebiSmart device is a new injection device which has been developed to help patients with injecting their Rebif treatment. Currently, all treatments for MS are injectable and require long term patient commitment. Patient compliance to treatment is important for the therapy to work effectively and decrease the risk of relapse episodes. Using a device that makes it easy for patients to inject may potentially improve compliance to treatment and therefore potentially have an impact on the number of relapses patients experience. The RebiSmart device has been developed for patients to inject conveniently and in comfort. The device allows the patient to control certain parameters such as needle depth, needle speed, injection time etc, and also has extra features designed to ease the injection process, such as a dose history calendar and an on-screen injection guide. The aim of this study is to determine what percentage of patients liked using the RebiSmart device and found it ''easy'' or ''very easy'' to use. The study will also determine which of the device features were most useful to the patients.

Conditions

Multiple Sclerosis

Keywords

Multiple sclerosis; Rebif; Interferon beta-1a

Outcome Measures

Primary Outcomes (1)

• Percentage of subjects who liked using the RebiSmart device based on a score of 6 or more on a Visual Analogue Scale (VAS) at the end of 12-week treatment period

  up to week 16

Secondary Outcomes (2)

• Percentage of patients who found RebiSmart easy or very easy to use at the end of 12-week treatment period

  up to week 16

• Top three functions of the device patients found most useful; top ranked from 1 to 10

  up to week 16

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients, who are under regular review by a Multiple Sclerosis nurse, with relapsing remitting multiple sclerosis who have been prescribed Rebif and have chosen to use the RebiSmart device for drug administration.

You may qualify if:

• Have relapsing remitting multiple sclerosis
• Between 18 to 65 years old inclusive
• Have been prescribed Rebif for the first time but not yet started treatment
• Rebismart as chosen device
• Be under review by MS nurse
• Having given written informed consent to participate in the study

You may not qualify if:

• Injections of Rebif given by someone other than the patient
• Patients unable to use the Rebismart device due to visual or physical impairment
• Patients unwilling to give informed consent
• Contra-indications to Rebif as defined in the Summary of Product Characteristics (SPC).
• Allergy to the antipyretic analgesics that will be advised as prophylaxis for flu-like symptoms

Sponsors & Collaborators

• Merck KGaA, Darmstadt, Germany: lead
• Merck Serono Limited, UK: collaborator

Related Publications (1)

• D'Arcy C, Thomas D, Stoneman D, Parkes L. Patient assessment of an electronic device for subcutaneous self-injection of interferon beta-1a for multiple sclerosis: an observational study in the UK and Ireland. Patient Prefer Adherence. 2012;6:55-61. doi: 10.2147/PPA.S26250. Epub 2012 Jan 18.

  PMID: 22298944 RESULT

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Dr Gillian L Shepherd, MD, MRCP

  Merck Serono Limited, UK

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 31, 2010
• First Posted: September 6, 2010
• Study Start: July 1, 2009
• Primary Completion: September 1, 2010
• Study Completion: October 1, 2010
• Last Updated: February 17, 2014

Record last verified: 2014-02